Skip to content

Validation of Scales in Reconstructive Breast Surgery

Validation of Scales in Reconstructive Breast Surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05233891
Acronym
ValPlast
Enrollment
500
Registered
2022-02-10
Start date
2021-06-21
Completion date
2027-12-21
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Hypertrophy

Keywords

plastic surgery, breast reconstruction, patient reported outcome, complication

Brief summary

The main purpose of the project is to validate patient reported outcomes measures (PROMs) in reconstructive breast surgery. BREAST-Q will be evaluated for Swedish and Sweden.Hospital Anxiety and Depression Scale (HADS), EuroQol 5D (EQ5D), and SF-36 will be validated for reconstructive breast surgery. In addition, the complication classification system according to Clavien-Dindo will be validated for reconstructive breast surgery.

Interventions

PROCEDUREBreast reconstruction

Breast reconstruction after breast cancer.

Breast reduction due to breast hypertrophy.

Sponsors

Vastra Gotaland Region
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Women who have had or will have reconstructive breast surgery in Sahlgrenska university hospital.

Exclusion criteria

* Do not understand Swedish.

Design outcomes

Primary

MeasureTime frameDescription
Validation and reliability of RAND-36 for reconstructive breast surgery5 years postoperativelyIt comprises eight subdomains: physical functioning (10 items), role limitations caused by physical health problems (4 items), role limitations caused by emotional problems (3 items), social functioning (2 items), emotional well-being (5 items), energy/fatigue (4 items), pain (2 items), and general health perceptions (5 items) where patients score their health during the last four weeks on Likert scales. Every item score is transformed linearly to the per cent of total possible score (0-100) and then averaged by the values of the scale. A subscore is calculated for each domain and in addition two summary scores, physical and mental health, are calculated.
Validation of Clavion-Dindo classification for reconstructive breast surgery5 years postoperativelyThe Clavien-Dindo system is based on ranking the severity of the intervention required to treat a given complication, as follows: grade I includes deviations from the postoperative course without the need for pharmacological treatment or surgical/endoscopic/radiological intervention; grade II complications require pharmacological treatment, blood transfusion, or total parental nutrition; grade III complications require surgical/endoscopic/radiological intervention; grade IV includes life-threatening complications, including those involving the central nervous system, that require intensive care treatment; and grade V includes complications that result in death.
Validation and reliability of BREAST-Q for SwedenPre-operativelyBreast-Q measures breast related quality of life on a scale 1-100. A higher score indicates a higher quality of life.
Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgeryPre-operativelyEuroQol-5 dimensions-3 levels (EQ5D) is a generic instrument developed for health economic and clinical evaluation of healthcare. A total score between 0 and 1 is calculated. Zero equals death and 1 perfect health.
Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgeryPre-operativelyThe HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21).

Countries

Sweden

Contacts

Primary ContactEmma Hansson, MD, PhD
emma.em.hansson@vgregion.se+46313421000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026